Penetration of Ceftaroline Into Cerebrospinal Fluid(CSF)

Meningitis Clinical Trial

— Ceftaroline  

Official title:

Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftaroline in Patients With CSF Device

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02806882
• Other study ID #: Chavanet AZ 2014
• Status: Completed
• Phase: Phase 1
• Start date: April 29, 2015
• Est. completion date: October 24, 2016

Study information

• Verified date: February 2024
• Source: Centre Hospitalier Universitaire Dijon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ceftaroline is a piece of new cephalosporin very active on resistant staphylococci in methicillin (SEMR: Staphylococcus Epidermidis Resistant in Methicillin, SMAR: Staphylococcus Aureus Resistant in Methicillin)and/or in vancomycin ; Ceftaroline is also very active on pneumococci resistant in penicillin and/or 3rd generation of cephalosporins.

Ceftaroline was approved by the European Medicines Agency for the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Scientific literature describes a good efficiency in septicemy and/or SAMR endocarditis.

Besides, a study on animal shows the efficiency of ceftaroline in meningeal infections with gram-negative Bacilli.

The rationale of this study is based on the antibacterial spectra of ceftaroline that could be used for the antibacterial treatment (curative and prophylactic) of CSF shunt associated infections.

To validate this hypothesis, it is necessary to evaluate the concentration of ceftaroline in meningeal compartment after treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: October 24, 2016
• Est. primary completion date: October 24, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients (= 18 years)

• Provision of informed consent prior to any study specific procedures

• Female patients of childbearing potential may be entered if pregnancy testing is negative and the patient agrees to abstain from procreational sexual intercourse or must use double-barrier contraceptive measures for the duration of the study

• Presence of an indwelling external cerebrospinal fluid (CSF) access device (ventriculostomy or lumbar drain)

• Presence of inflamed meninges as a result of documented or suspected meningitis or ventriculitis. Patients with both clinical symptoms (fever, headache, meningismus, and altered mentation) and laboratory parameters (CSF leukocytosis, defined as a CSF white blood cell count [WBC] of >10 3, elevated CSF protein, defined as CSF protein of >1g/l, reduced CSF glucose, defined as CSF glucose of <0.3g/l, or a positive CSF Gram stain or culture) indicative of CNS infection were deemed to have definitive bacterial meningitis/ventriculitis. Inflamed meninges were defined as the presence of >5 leukocytes/mm3 of CSF.

Exclusion Criteria:

• Patient has documented history of hypersensitivity or allergic reaction (urticaria, angiooedema, anaphylaxis, desquamative rash) to any ß-lactam antimicrobial including cephalosporins (contraindication to cephalosporins)

• Patient is pregnant or lactating and intends to continue breastfeeding

• Severe renal insufficiency defined as creatinine clearance < 50 mL/min.

• Patients with conditions known or suspected to alter pharmacokinetics (i.e., burn or cystic fibrosis patients)

• Refusal to participate

• Person not affiliated with the social security

Related Conditions & MeSH terms

• Meningitis
• Ventriculitis

Intervention

Drug:
• Ceftaroline fosamil
600mg IV infusion

Locations

Country	Name	City	State
France	CHU Dijon	Dijon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ceftaroline serum concentration		before infusion, at 0.5h, 1h, 3h, 6h, 12h, 24h after infusion
Primary	Ceftaroline cerebrospinal fluid concentration		before infusion, at 0.5h, 1h, 3h, 6h, 12h, 24h after infusion